Tag:
Fosamax
Latest Headlines
Latest Headlines
Merck wins bellwether Fosamax femur-fracture trial
The jury in the latest Fosamax trial has spoken, and it spoke for Merck. In a federal court in New Jersey, the panel determined that plaintiff Bernadette Glynn's broken leg wasn't caused by the bone drug Fosamax. It was the first jury verdict among the more than 3,000 lawsuits claiming Fosamax caused serious femur fractures.
Merck kept mum on Fosamax's fracture risks, trial lawyer says
A plaintiff's lawyer in the latest lawsuit claims Merck was warned about the potential for spontaneous fractures 5 years before Fosamax made its debut.
Merck hid Fosamax's links to femur fractures, lawyer says
It's Fosamax trial time again. Amid litigation over the bone drug's risks of jawbone injury, Merck is in court to fight claims that Fosamax caused patients' femur fractures. Once again, the drugmaker faces charges that it ignored the drug's safety risks, leaving patients in the dark.
Merck loses 'bellwether' Fosamax case
You win some and you lose some and this time, Merck ($MRK) lost to the tune of $285,000 when a jury said it was not up front about the risks of osteoporosis drug Fosamax.
As blockbuster drugs fade, so does TV advertising
The DTC juggernaut is weakening. As The New York Times reports, industry spending on TV ads fell by 2% in 2011, the fourth consecutive year of decline. Altogether, TV spending is down 20% from 2007...
Merck prevails in fourth Fosamax trial
Another bellwether Fosamax case is wrapped up, with another victory for Merck. A Manhattan jury found for the company ( $MRK ) in a case filed by Florida patient Linda Secrest, who claimed she suffered
Judge jettisons claims in bellwether Fosamax case
Merck ( $MRK ) has won a significant victory in the fourth Fosamax case to hit court. U.S. District Judge John Keenan tossed all but one claim against the company, leaving it to fight patient Linda
Roche keeps up DTC on Boniva while others cut
Marketing osteoporosis drugs has grown more complicated since Merck's Fosamax went off patent a couple years ago. Now that there are low-cost alternatives to branded bisphosphonate treatments,
Fosamax judge wants two more bellwethers
The judge overseeing litigation over Merck's bone drug Fosamax needs more tea leaves to read. Judge John Keenan originally thought a half-dozen bellwether cases would be enough to outline the
Docs revisit strategies for bone-drug use
The popularity and effectiveness of bisphsophonate drugs such as Fosamax for generally healthy women without osteoporosis or broken bones have become a source of increasing argument in doctors'
